fbpx

QQQ
+ 3.42
362.73
+ 0.93%
BTC/USD
+ 834.37
43849.99
+ 1.94%
DIA
+ 3.35
335.76
+ 0.99%
SPY
+ 4.25
429.38
+ 0.98%
TLT
+ 0.90
149.99
+ 0.6%
GLD
-0.65
166.69
-0.39%

Cantor Fitzgerald Lowers Price Target On Tilray Cannabis Co Ahead Of Earnings Report, Sees Several Catalysts Including U.S. Plans

July 27, 2021 11:15 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
Cantor Fitzgerald Lowers Price Target On Tilray Cannabis Co Ahead Of Earnings Report, Sees Several Catalysts Including U.S. Plans

Canadian cannabis giant Tilray, Inc. (NASDAQ: TLRY) is scheduled to report its quarterly earnings on July 28th, before the market opens. Year-to-date, the stock is up 35.12%.

Tilray, based in New York and Leamington, Ontario, recently confirmed that another independent proxy advisory firm is recommending that shareholders back all of the company’s proposals at a special meeting scheduled for July 29. This time, the proxy advisory services company Glass Lewis also advised shareholders to vote in favor of the company’s dilution as well as other proposals. 

The Analyst

Cantor Fitzgerald’s Pablo Zuanic kept an ‘Overweight’ rating on Tilray's stock but lowered the price target to $19 from $24.

The Thesis 

The combined company’s May quarter report will include a full quarter of the old Aphria (through May) and one month of the old Tilray as well as Pro-forma numbers by division for the 12-month period ending May, wrote Zuanic in a Tuesday analyst note.

See also: How to Buy Tilray Here (ACB) Stock 

“So, we will not be able to judge cannabis sales trends (what really matters, in our view).”

Tilray is expected to report a flat quarter with share loss coming from Aphria and gains from Tilray, noted Zuanic, explaining that lowering the price target is due to the recent sectorial derating.

The analyst expressed concern that the headline consensus numbers are not accurate “as it is a blended comparison of apples to oranges.” The FactSet consensus projected $193.3 million sales for the quarter, which, according to Zuanic, “does not seem right” since there was no sequential growth. Without it, the numbers should be around $140 million.

“Our pro forma numbers for the May quarter are $175Mn (or about 5% down sequentially).”

The analyst further listed several possible catalysts from the financial report: 

  • Domestic recreational outlook;
  • U.S. plans;
  • Overseas growth commentary;
  • Dealing with the convertible debt. 

The Price Action 

Tilray’s shares were trading 6.68% lower at $12.79 per share at the time of writing.

Photo: Courtesy of Esteban Lopez on Unsplash

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to Benzinga Podcasts and our YouTube channel.


Related Articles

Canopy Growth's Stock Dips After Analyst Cuts Price On Lower Sales, Confesses Preference For Tilray

Canopy Growth's Stock Dips After Analyst Cuts Price On Lower Sales, Confesses Preference For Tilray

After Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) revealed that its cannabis sales of CA$136 million ($108 million) did not reach a cons read more
Organigram On Pace To Beat Tilray And Hexo In QoQ Sales Growth As Canadian Rec. Sales Reach $275.6M

Organigram On Pace To Beat Tilray And Hexo In QoQ Sales Growth As Canadian Rec. Sales Reach $275.6M

As COVID-related restrictions begin to ease across the globe, some industries are feeling the benefits more than others. When it comes to Canadian recreational cannabis sales, new Hifyre scanner data reveals a 10% improvement sequentially, noted Cantor Fitzgerald’s Pablo Zuanic in his latest industry report. read more
Analyst Says MedMen's Momentum Changing, Tilray's Stake Won't Double Its Value But Will Hold Premium

Analyst Says MedMen's Momentum Changing, Tilray's Stake Won't Double Its Value But Will Hold Premium

MedMen Enterprises Inc. (OTCQX: MMNFF) revealed Tuesday that it has secured $100 million in financing via a private sale of its units in a deal led by Serruya Private Equity. read more
Cantor Fitzgerald Says Tilray's Stake In MedMen One Of The Steps In US Journey, Could Be Getting Close To Altria

Cantor Fitzgerald Says Tilray's Stake In MedMen One Of The Steps In US Journey, Could Be Getting Close To Altria

Canadian cannabis giant Tilray, Inc. NASDAQ: TLRY) announced Tuesday it has acquired the majority of the outstanding senior secured convertible notes of</ read more